Related Experiment Video
Updated: May 29, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
New evidence for miRNA testing in head and neck squamous cell cancer patients
Blanca Pilar Galindo Torres1, Raquel Alcaraz Ortega2, Patricia Saiz López3
1Servicio Otorrinolaringología, Hospital Universitario de Burgos, Burgos, Spain. bgalindot@saludcastillayleon.es.
Purpose:
Prognosis of HNSCC has not changed over the last decades. MicroRNAs mediate gene expression and participate in regulating cellular biological processes. Its aberrant expression is an important event in the development of several cancers, including head and neck squamous cell cancer. The aim of the study is to determine if circulating miRNAs are reliable diagnostic indicators and can be used to monitor head and neck cancer.
Methods/Patients:
An observational, longitudinal, prospective, analytical study was conducted, with a case-control design, in which 37 head and neck squamous cell cancer patients at diagnosis were compared with 30 healthy patients. Blood samples were obtained and free miRNA expression levels of 17 miRNAs were determined by PCR-RT. Follow-up of HNSCC was carried out for one year with blood extractions at 7 days for surgical patients, and 1, 2, 6 and 12 months after finishing treatment for all patients.
Results:
Seventy-eight percent of the participants in HNSCC group and 57% among control group were men. Smokers and alcohol consumers exhibit increased susceptibility to HNSCC, and risk rises to 63.4% (R2 = 0.634) when both factors are combined. HNSCC patients overexpressed miR-21-5p and miR-122, while miR-195-5p is downregulated. Elevated miR-21-5p levels correlates with tumour size and miR-374b-5p, with advanced stage (p = 0.005).
Conclusion:
Our findings suggest that the evaluation of certain miRNAs' expression levels in plasma can be used as potential markers for HNSCC diagnosis. Further assays with larger samples could be performed to validate data and establish a cut-off expression level for our proposed miRNAs.
